Flow Cytometric Evaluation of Biomarkers

生物标志物的流式细胞术评估

• 批准号: 9556831
• 负责人: Maryalice Stetler-Stevenson
• 金额: $ 46.86万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9556831
• 关键词: Antibodies; Antigens; Benign; Binding; Biological Assay; Blood; Cell Therapy; Cells; Characteristics; Clinical; Data; Development; Diagnosis; Disease; Flow Cytometry; Fluorescent Antibody Technique; Goals; Institution; Label; Lymphoma; Medical; Monitor; Neoplasms; Pathway interactions; Patients; Play; Population; Protocols documentation; Radioactive; Radioactivity; Regimen; Research Personnel; Resources; Role; Sampling; Site; Staining method; Stains; System; Techniques; Testing; Therapeutic; Therapeutic Agents; Therapeutic antibodies; Time; base; biomarker evaluation; cancer cell; cell determination; chimeric antigen receptor; improved; insight; leukemia; leukemia/lymphoma; neoplastic cell; new technology; novel therapeutics; prognostic; protein profiling; response; therapeutic evaluation; treatment response

Clinical quantitative flow cytometry is a new technology that utilizes specialized antibody staining techniques and fluorescent standards to quantitate antibody binding to different cell populations within a sample. The Flow Cytometry Unit uses this technique to quantitate tumor cell antibody binding capacity in patients undergoing various antibody based therapies. The flow cytometric assays are performed in place of previous studies using radioactively labeled antibodies. The flow cytometric assays are more rapid, make the use of radioactivity unnecessary and are performed on 100 uL of blood instead of 25mL. The data collected is also more precise and improves the ability of NCI investigators to compare antibody binding to tumor cells to treatment response. Quantitation of fluorescent antibody binding immediately post therapy also allows precise determination of saturation of antigen sites with non labeled therapeutic antibody. Antibody based therapy is now incorporated into routine treatment for patients with leukemia or lymphoma and the majority of NCI lymphoma and leukemia protocols include it in their regimens. Antigen Quantitation is therefore a tremendous resource for NCI investigators that is available at other institutions. Quantitation of antigens prior to, during and post therapy may provide insight into pathways disrupted by novel therapeutic agents. Flow cytometric testing is also utilized to evaluate patients receiving chimeric antigen receptor (CAR) T cell therapy at NCI. It plays a vital role in assessing response to chimeric antigen receptor (CAR) T cell therapy by quantitating expansion of the therapeutic CAR T cells in the patient while at the same time monitoring the decrease in neoplastic cells.

临床定量流式细胞术是一项利用专门的抗体染色技术和荧光标准来定量抗体与样品中不同细胞群结合的新技术。流式细胞术单位使用这种技术定量肿瘤细胞抗体结合能力的病人接受各种抗体为基础的治疗。流式细胞术检测代替了以前使用放射性标记抗体的研究。流式细胞术检测更快速，不需要使用放射性，并且在100 uL的血液中进行，而不是25mL。收集的数据也更精确，提高了NCI研究人员比较抗体与肿瘤细胞结合和治疗反应的能力。治疗后立即定量荧光抗体结合也可以精确测定抗原位点的饱和度与非标记的治疗性抗体。基于抗体的治疗现在被纳入白血病或淋巴瘤患者的常规治疗，大多数NCI淋巴瘤和白血病方案将其纳入其方案。抗原定量因此是一个巨大的资源，为NCI研究人员，可在其他机构。在治疗前、治疗期间和治疗后对抗原进行定量分析，可以深入了解被新型治疗剂破坏的途径。流式细胞术检测也用于评估在NCI接受嵌合抗原受体（CAR） T细胞治疗的患者。它在评估对嵌合抗原受体（CAR） T细胞治疗的反应中起着至关重要的作用，通过定量患者体内治疗性CAR T细胞的扩增，同时监测肿瘤细胞的减少。